BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The ANDA was filed as 'First to File' submission on NCE-1 date.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Subscribe To Our Newsletter & Stay Updated